Citius Pharmaceuticals (CTXR) Change in Accured Expenses (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 17 years of Change in Accured Expenses data on file, last reported at $507612.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 79.99% year-over-year to $507612.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.3 million (down 146.72% YoY) and the FY2025 annual result came in at $4.2 million, up 5693.33% from the prior year.
• Change in Accured Expenses improved to $507612.0 in Q1 2026, from -$198052.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.2 million in Q4 2024 to a low of -$4.3 million in Q3 2025.
• A 5-year average of $189314.0 and a median of -$2150.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses surged 2174.54% — and 2025, when it sank 201454.51%.
• Tracing CTXR's Change in Accured Expenses over 5 years: stood at -$714992.0 in 2022, then jumped by 138.28% to $273688.0 in 2023, then surged by 2174.54% to $6.2 million in 2024, then tumbled by 103.18% to -$198052.0 in 2025, then soared by 356.3% to $507612.0 in 2026.
• The last three Change in Accured Expenses figures came in at $507612.0 (Q1 2026), -$198052.0 (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.